Integrated OTC Stock Performance

INBP -  USA Stock  

USD 1.08  0.01  0.92%

Integrated Biopharma has performance score of 3 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of -0.1283, which attests to not very significant fluctuations relative to the market. Let's try to break down what Integrated's beta means in this case. As returns on the market increase, returns on owning Integrated Biopharma are expected to decrease at a much lower rate. During the bear market, Integrated Biopharma is likely to outperform the market. Although it is extremely important to respect Integrated Biopharma current price history, it is better to be realistic regarding the information on equity current price movements. The philosophy towards determining future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By evaluating Integrated Biopharma technical indicators, you can presently evaluate if the expected return of 0.17% will be sustainable into the future. Integrated Biopharma right now retains a risk of 3.13%. Please check out Integrated Biopharma information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to decide if Integrated Biopharma will be following its current trending patterns.

Integrated O TC Stock Performance 

 Integrated Performance
3 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in Integrated Biopharma are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very fragile fundamental drivers, Integrated Biopharma may actually be approaching a critical reversion point that can send shares even higher in November 2021. ...more

Integrated Price Channel

Quick Ratio0.46
Fifty Two Week Low0.4200
Fifty Two Week High1.2500

Integrated Biopharma Relative Risk vs. Return Landscape

If you would invest  100.00  in Integrated Biopharma on July 27, 2021 and sell it today you would earn a total of  8.00  from holding Integrated Biopharma or generate 8.0% return on investment over 90 days. Integrated Biopharma is currently generating 0.1669% in daily expected returns and assumes 3.1329% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of otc stocks are less volatile than Integrated, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 90 days Integrated Biopharma is expected to generate 4.4 times more return on investment than the market. However, the company is 4.4 times more volatile than its market benchmark. It trades about 0.05 of its potential returns per unit of risk. The DOW is currently generating roughly 0.04 per unit of risk.

Integrated Biopharma Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Integrated Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Integrated Biopharma, and traders can use it to determine the average amount a Integrated Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0533

Good Returns
Average Returns
Small ReturnsINBP
Negative Returns
Estimated Market Risk
  actual daily
 26 %
of total potential
Expected Return
  actual daily
 3 %
of total potential
Risk-Adjusted Return
  actual daily
 3 %
of total potential
Based on monthly moving average Integrated Biopharma is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Integrated Biopharma by adding it to a well-diversified portfolio.

About Integrated Biopharma Performance

To evaluate Integrated Biopharma OTC Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Integrated Biopharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Integrated OTC Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Integrated Biopharma stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Integrated's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Return on Average Assets 0.32  0.26 
Return on Average Equity 0.81  0.72 
Return on Invested Capital 0.37  0.31 
Return on Sales 0.12  0.1 
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey. Integrated Biopharma operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 143 people.

Things to note about Integrated Biopharma

Checking the ongoing alerts about Integrated Biopharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Integrated Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Integrated Biopharma Alerts

Equity Alerts and Improvement Suggestions

Integrated Biopharma has some characteristics of a very speculative penny stock
Integrated Biopharma has very high historical volatility over the last 90 days
Integrated Biopharma has high likelihood to experience some financial distress in the next 2 years
Integrated Biopharma has a frail financial position based on the latest SEC disclosures
About 68.0% of the company shares are held by company insiders
Latest headline from I-Mab Expands U.S. Footprint with New RD Site in San Diego -
Please see Risk vs Return Analysis. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Complementary Tools for Integrated OTC Stock analysis

When running Integrated Biopharma price analysis, check to measure Integrated Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integrated Biopharma is operating at the current time. Most of Integrated Biopharma's value examination focuses on studying past and present price action to predict the probability of Integrated Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Integrated Biopharma's price. Additionally, you may evaluate how the addition of Integrated Biopharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Bond Directory
Find actively traded corporate debentures issued by US companies
Transaction History
View history of all your transactions and understand their impact on performance
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Global Correlations
Find global opportunities by holding instruments from different markets
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Is Integrated Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Integrated Biopharma. If investors know Integrated will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Integrated Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Integrated Biopharma is measured differently than its book value, which is the value of Integrated that is recorded on the company's balance sheet. Investors also form their own opinion of Integrated Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Integrated Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Integrated Biopharma's market value can be influenced by many factors that don't directly affect Integrated Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Integrated Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Integrated Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Integrated Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.